Dr. Zelenko Covid-19 Prophylaxis
Protocol for Low and Moderate Risk Patients:
* Elemental Zinc 25 mg once a day
* Vitamin C 1000 mg once a day
* Quercetin 500 mg (OTC) once a day
~ If Quercetin is unavailable, then use Epigallocatechin-gallate (EGCG) 400 mg (OTC) once a day [EGCG is found in Green Tea extract]
Protocol for High Risk Patients:
* Elemental Zinc 25mg once a day
* Hydroxychloroquine (HCQ) 200 mg once a day for 5 days, then once a week.
~ If HCQ is unavailable then use Low and Moderate risk protocol [see above]
Ivermectin
Ivermectin as Prophylaxis:
Vora, Agam, et al. “White paper on Ivermectin as a potential therapy for COVID-19.” Indian Journal of Tuberculosis 67.3 (2020): 448-451.
— “After critical panel discussion, all the attending doctors came to a conclusion that Ivermectin can be a potential molecule for prophylaxis and treatment of people infected with Coronavirus, owing to its anti-viral properties coupled with effective cost, availability and good tolerability and safety.”
This video from Dr. Jennifer Hibberd describes a scabies outbreak in a nursing home. This is an anecdotal report. The nursing patients were treated with ivermectin. The 4th floor patients, where the outbreak occurred received a full single-dose of ivermectin (probably 18 mg). The other patients were given a prophylactic dose of ivermectin (probably 6 mg). The staff were not treated. Then there was a Covid-19 outbreak in the nursing home. None of the patients on the 4th floor, those treated with the full dose of ivermectin, contracted Covid-19 at all, even though most of their staff were sick with Covid-19. The other floors had fewer patients become ill with Covid-19 than staff, even though the staff had a much younger median age than the patients, and all the patients had co-morbidities.
Ivermectin as Treatment:
* Review of Ivermectin Clinical Trials data
* Gorial, Faiq I., et al. “Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial).” medRxiv (2020).
~ All the patients of IVM group were cured; none of the Ivermectin patients died. “The mean time to stay in the hospital was significantly lower in IVM group compared with the controls”, 7.62 days for IVM and 13.22 days for control. Results were highly statistically significant.
* Scheim, David. “Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion.” Available at SSRN 3636557 (2020).
“Overall mortality was 15% in the IVM group, 40% less (p=0.03) than the 25.2% mortality in the control group. For 75 patients with severe pulmonary disease (receiving oxygen at FiO2 = 50% or ventilation), those treated with IVM (n=46) had a mortality of 38.8%, 52% less (p=0.001) than the 80.7% mortality in corresponding controls (n=29). Stabilization and then improvement often proceeded in 1-2 days, even for patients who had been deteriorating rapidly from room air to supplemental oxygen at up to a 50% mixture (FiO2 = 0.5). The 1-2-day reversals of declining oxygen status in these Florida patients is consistent with rapid absorption and distribution into tissue of orally administered IVM.”
Rajter, Juliana Cepelowicz, et al. “ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19.” medRxiv (2020). medRxiv.org
Conclusion: “Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support.”
Chowdhury, Abu Taiub Mohammed Mohiuddin, et al. “A comparative observational study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.” ResearchGate.net
Conclusion: “Concerning the treatment outcome, adverse effect, and safety, IvermectinDoxycycline combination is superior to Hydroxychloroquine-Azithromycin therapy in the case of mild to moderate degree of COVID19 patients. ”
